68-Ga-NYM032 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prostate Cancer (Diagnosis)
- Main trialPhase 3
- “The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.”In the company’s words, NCT07615101 on ClinicalTrials.gov
Other drugs for Prostate Cancer (Diagnosis)
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jun 2027 | Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | |
| Phase 1/2Completed | 28 Oct 2024 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026